β-(thien-2-yl) acrylamide | 24654-26-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: β-(thien-2-yl) acrylamide
• 英文别名: 3-(2-Thienyl)acrylamide；3-thiophen-2-ylprop-2-enamide
• CAS: 24654-26-0
• 化学式: C₇H₇NOS
• 分子量: 153.205
• InChiKey: AEKLLKXWNJVXKT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  β-(thien-2-yl) acrylamide 在 盐酸羟胺 、 羟胺 、 sodium methylate 、 三氯氧磷 作用下， 以 甲醇 、 氯仿 、 水 为溶剂， 生成 β-(thien-2-yl) acrylamidoxime
  参考文献：
  名称：

  Oxadiazole and oxadiazoline derivatives

  摘要：

  描述了一种新的化合物，其化学式为##STR1##其中E是从以下组中选择的残基：##STR2##其中R"是从氨基、乙烯基、烯丙基、乙炔基、C.sub.1 -C.sub.5烷基、C.sub.1 -C.sub.5烷氧基或C.sub.1 -C.sub.5烷硫基或至少一个卤原子取代的C.sub.1 -C.sub.5烷基；和氢；其中R.sup.1和R.sup.2分别从氢、卤素、甲基和乙基中选择；R'是选择的取代苯基，当R"不是氢时，以及苯基、噻吩基和取代苯基和噻吩基，当R"是氢时。这些化合物在控制寄生虫方面具有用途。其中一些化合物具有抗微生物特性。

  公开号：

  US04012377A1

文献信息

• Hydrogel Nanocompsites for Ophthalmic Applications
  申请人：Ravi Nathan

  公开号：US20070269488A1

  公开（公告）日：2007-11-22

  The present invention relates to reversible hydrogel systems. Particularly, the hydrogel of the present invention is made up of copolymers that can be a hydrogel when in an oxidized state and can be a solution when in a reduced state. A solution of the copolymer can be oxidized to form a hydrogel; and the hydrogel can be reduced to form a solution of the copolymer. Reversible nanogels can also be formed from a dilute solution of the copolymers. The hydrogel is formed with nanoparticles embedded therein to form a nanocomposite whose refractive index and modulus can be controlled by varying the amounts of nanoparticles and the polymer concentration of the hydrogel, respectively

  本发明涉及可逆水凝胶系统。特别是，本发明的水凝胶由共聚物组成，在氧化状态时可以是水凝胶，在还原状态时可以是溶液。共聚物的溶液可以被氧化成水凝胶；水凝胶可以被还原成共聚物的溶液。还可以从稀溶液的共聚物形成可逆纳米凝胶。水凝胶中嵌入了纳米颗粒以形成折射率和模量可以通过改变纳米颗粒的量和水凝胶的聚合物浓度来控制的纳米复合材料。
• BICYCLIC PYRAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS
  申请人：Allison Brett D.

  公开号：US20100280240A1

  公开（公告）日：2010-11-04

  Antibacterial compounds, compositions containing them, and methods of use for the inhibition of bacterial activity and the treatment, prevention or inhibition of bacterial infection.

  抗菌化合物，含有它们的组合物，以及用于抑制细菌活性和治疗、预防或抑制细菌感染的使用方法。
• Acrylamide Compounds And Use Thereof For Inhibiting Apoptosis
  申请人：He Kunlun

  公开号：US20130158022A1

  公开（公告）日：2013-06-20

  The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate of the compound, and to a composition comprising the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. The present invention also relates to use of the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, and for preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.

  本发明涉及化合物I的一种，或其异构体，药学上可接受的盐和溶剂，以及包含化合物I的组合物，或其异构体，药学上可接受的盐和溶剂，以及药学上可接受的载体，赋形剂或稀释剂。本发明还涉及使用化合物I的一种，或其异构体，药学上可接受的盐和溶剂来对抗细胞凋亡，预防或治疗与细胞凋亡相关的疾病或障碍；特别是用于保护心肌细胞，并预防或治疗与心肌细胞凋亡相关的疾病或障碍。
• ACRYLAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING APOPTOSIS
  申请人：CHINESE PLA GENERAL HOSPITAL

  公开号：US20160038445A1

  公开（公告）日：2016-02-11

  The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate of the compound, and to a composition comprising the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. The present invention also relates to use of the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, and for preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.

  本发明涉及公式I的化合物，或其异构体，药学上可接受的盐和溶剂，以及包含公式I的化合物，或其异构体，药学上可接受的盐和溶剂以及药学上可接受的载体，赋形剂或稀释剂的组合物。本发明还涉及使用公式I的化合物，或其异构体，药学上可接受的盐和溶剂，用于对抗凋亡，预防或治疗与凋亡相关的疾病或疾病; 特别用于保护心肌细胞，并预防或治疗与心肌细胞凋亡有关的疾病或疾病。
• REMEDIES OR PREVENTIVES FOR LIVER DISEASES CONTAINING DIAMINOTRIFLUOROMETHYLPYRIDINE DERIVATIVES
  申请人：ISHIHARA SANGYO KAISHA, LTD.

  公开号：EP1252891A1

  公开（公告）日：2002-10-30

  A therapeutic or preventive agent for liver diseases, containing as an active ingredient a diaminotrifluoromethylpyridine derivative represented by the formula (I) or its salt: wherein X is a -CW1R1 group, a -COCOR2 group, a -CW1NHCOR2 group, a -C(=W1)W2R3 group or a -CW1N(R4)R5 group; Y is an alkyl group, a -CW3R6 group, a -COCOR7 group, a -NHCOR7 group, a -C(=W3)W4R8 group, a -(NH)mSO2R9 group, a -(NH)mSO2OR10 group or a -(NH)mSO2N(R11)R12 group; each of R1, R6 and R9 is a chain hydrocarbon group, a monocyclic hydrocarbon group, a polycyclic hydrocarbon group, a monocyclic heterocycle group or a polycyclic heterocycle group; each of R2 and R7 is an alkyl group, an alkoxy group, a phenyl group or a phenoxy group; each of R3, R8 and R10 is an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a phenyl group or a benzyl group; each of R4, R5, R11 and R12 is an alkyl group; each of W1, W2, W3 and W4 is an oxygen atom or a sulfur atom; . and m is 0 or 1, is provided.

  一种治疗或预防肝病的药物，其有效成分含有由式(I)或其盐代表的二氨基三氟甲基吡啶衍生物： 其中 X 是-CW1R1 基团、-COCOR2 基团、-CW1NHCOR2 基团、-C(=W1)W2R3 基团或-CW1N(R4)R5 基团；Y 是烷基、-CW3R6 基团、-COCOR7 基团、-NHCOR7 基团、-C(=W3)W4R8 基团、-(NH)mSO2R9 基团、-(NH)mSO2OR10 基团或-(NH)mSO2N(R11)R12 基团；R1、R6 和 R9 中的每一个是链烃基团、单环烃基团、多环烃基团、单环杂环基团或多环杂 环基团；R2和R7各自为烷基、烷氧基、苯基或苯氧基； R3、R8和R10各自为烷基、烯基、炔基、环烷基、苯基或苄基； R4、R5、R11和R12各自为烷基； W1、W2、W3和W4各自为氧原子或硫原子； .和 m 为 0 或 1。